† VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies

Patrick Flight, Ellen Rohde, Richard Lee, Anne Marie Mazzola, Colin Platt, Taiji Mizoguchi, K J Pendino, Alexandra C. Chadwick, Amit V. Khera, Scott B. Vafai, Sekar Kathiresan, Troy Lister, Joseph C. Biedenkapp